NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) — Cytovia Therapeutics, an emerging biopharmaceutical company and the New York Stem Cell Foundation (NYSCF) Research institute today announced the filing of a provisional patent application with the U.S. Patent & Trademark Office (USPTO) for the differentiation of Natural Killer (NK) cells from induced pluripotent stem cells (iPSCs). The NYSCF Research Institute is a pioneer and acknowledged leader in stem cell technology, having developed the NYSCF Global Stem Cell Array®, the premier automated robotic platform for reprogramming skin or blood into induced pluripotent stem cells (iPSCs) and differentiating them into disease-relevant cell types.
Cytovia and NYSCF are also collaborating on the process development of Good Manufacturing Practices (GMP) of iPSC NK and CAR-NK cells with the potential to file additional patents on the engineering, expansion and GMP manufacturing processes of iPSC NK cells to treat cancer.
Dr. Daniel Teper, CEO of Cytovia commented, “This first patent application filing on iPSC-NK cells is an important milestone for Cytovia, positioning us as a pioneer in this emerging field. The use of iPSC-NK cells constitutes a transformational approach to cancer treatment, enabling the use of precision cell therapy for many patients. Cytovia plans to initiate first clinical trials with iPSC NK-cells in 2021. “
Susan L Solomon, Chief Executive Officer of NYSCF added, “We are delighted by the progress made by the NYSCF and Cytovia team in the differentiation and expansion of NK cells from